Necessary documents for ordering:<ol><li>Approval form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_6.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_d.docx">English</A>)</li><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li></ol><A HREF="https://shirasawa-acl.net/index.html" target="_blank">Lab HP (Japanese)</A>, <A HREF="https://shirasawa-acl.net/eng/index.html" target="_blank">Lab HP (English)</A> 白澤　卓二 Psen1 null herpes simplex virus thymidine kinase promoter (HSV tk promoter), E. coli neo, mouse presenilin 1 genomic DNA C（3〜6か月） Takuji SHIRASAWA true <a href='https://brc.riken.jp/mus/pcr00951'>Genotyping protocol -PCR-</a> 条件を付加する。利用者は事前に寄託者の提供承諾書を得る。<br>研究成果の公表にあたって寄託者の指定する文献を引用する。Koizumi et al, Development, 128, 1391-1402 (2001). <br>利用者は寄託者と共同研究を行う。ただし、共著を必要とする共同研究は寄託後２年間に限定する。<br>利用者が当該リソースと使用した研究成果に基づく特許等の申請を行う場合は寄託者と別途協議を行う。 RBRC00951 B6;129-Psen1<tm1Shs>/Shs B6.Cg-Psen1<tm1Shs>. Presenilin 1 has been found as a major causal gene for early-onset familial Alzheimer's disease (FAD), involving in the control of the cell cycle in neuronal precursor cells during development. Homozygous mutant embryos exhibit small body size and intracranial hemorrhages at late gestation. Backcross to C57BL/6 (Heterozygote x C57BL/6JJcl) Developed by Takuji Sirasawa, Tokyo Metropolitan Institute of Gerontology at 2002. A tk-neo cassette from pMC1-neo was inserted into the exon 9 of the Psen1 gene. Tokyo Metropolitan Foundation for Social Welfare and Public Health C (3-6 months) (財)東京都高齢者研究福祉振興財団 Psen1 null Psen1 null The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Koizumi et al, Development, 128, 1391-1402 (2001). The users must collaborate with the supplier for two years from the date of supply. <br>The users must discuss with the supplier when the users propose patents or present findings based on the results of investigation using the resource.